While CD16A-targeting BsAbs such as AFM13 (targeting CD30/CD16A) have demonstrated clinical efficacy in hematologic malignancies (18, 19), their application in solid tumors like HCC remains largely unexplored. This evidence concerns the gene FCGR3A and hepatocellular carcinoma.